Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

3 of 12 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
10(76.9%)
Phase 2
3(23.1%)
13Total
Phase 1(10)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT00920556Phase 2Terminated

A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma

Role: lead

NCT00937326Phase 2Completed

Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects

Role: lead

NCT01340911Phase 1Completed

A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases

Role: lead

NCT01154101Phase 2Completed

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

Role: lead

NCT01262911Phase 1Completed

Effect of SRT2379 on Endotoxin-Induced Inflammation

Role: lead

NCT00938275Phase 1Completed

A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers

Role: lead

NCT01031108Phase 1Completed

A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT01416376Phase 1Completed

Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation

Role: lead

NCT00920803Phase 1Completed

A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases

Role: lead

NCT01702493Phase 1Completed

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

Role: lead

NCT00937872Phase 1Completed

A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects

Role: lead

NCT01453491Phase 1Completed

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

Role: lead

NCT00933530Phase 1Completed

A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers

Role: lead

All 13 trials loaded